일주기 리듬 수면장애 시장 예측(-2030년) : 치료 유형, 약물 유형, 연령, 유통 채널, 용도, 최종사용자, 지역별 세계 분석

According to Stratistics MRC, the Global Circadian Rhythm Seep Disorder Market is accounted for $761.87 million in 2023 and is expected to reach $1191.74 million by 2030 growing at a CAGR of 6.6% during the forecast period. The term circadian rhythm sleep disorders (CRSDs) refers to conditions where the body's internal clock, the circadian rhythms, are abnormal. Sleep disorders related to the circadian rhythm are brought on by changes in the external environment and the central circadian timekeeping system. When a person struggles to go to sleep at a regular time and interferes with their sleep schedule, they usually have circadian rhythm sleep disorders. And, there are various types of circadian rhythm sleep disorders, including jet lag, shift work disorder, advanced sleep phase disorder (ASPS), delayed sleep phase disorder (DSPD), and the free-running type.

According to a sleep heart study, those who had a history of insomnia or poor sleep had a 29 % increased risk of cardiovascular disease (CVD). These kinds of figures encourage those suffering from sleep disorders to seek expert assistance, hence raising the market's demand.

Market Dynamics:

Driver:

Increasing awareness and diagnosis

Increased public health efforts, education campaigns, and the spread of information via digital platforms are all responsible for the rising awareness of circadian rhythm sleep disorders. Additionally, rising diagnosis rates are a result of patients and medical professionals' increased awareness of the telltale signs and symptoms of CRSDs. Growing numbers of people are seeking suitable treatment and management options as diagnosis becomes more widely available, which propels market expansion.

Restraint:

Inadequate knowledge and awareness

A major barrier to the CRSD market is the lack of knowledge and awareness regarding sleep disorders related to the circadian rhythm. Both the general public and medical professionals might not be aware of the symptoms or might mistake them for other illnesses. Moreover, this ignorance may result in under diagnosis and postponed treatment, impeding the expansion of the market.

Opportunity:

Advances in research and development

The development of novel diagnostic instruments, therapeutic interventions, and pharmaceuticals specifically designed for various subtypes of CRSDs is made possible by ongoing research into circadian rhythms, genetics, and the neurobiology of sleep disorders. Additionally, this study holds the key to improved patient outcomes and more potent treatments.

Threat:

Insufficient knowledge and misdiagnosis

The low awareness of these disorders among the general public and medical professionals poses a serious threat to the CRSD market. Many people with CRSDs go undiagnosed or are misdiagnosed, and they frequently blame their symptoms on other medical conditions. However, inadequate knowledge impedes prompt diagnosis and efficient therapy.

COVID-19 Impact:

The Circadian Rhythm Sleep Disorder (CRSD) market was impacted by the COVID-19 pandemic in a number of ways. Delays in diagnosing and treating CRSDs occurred during the height of the pandemic due to decreased patient visits, changes in healthcare services, and the prioritization of COVID-19 cases. Patient access to care was impacted by the temporary closure of sleep clinics and the implementation of restrictions on their operations. Additionally, a rise in sleep disorders was attributed to changes in lifestyle and psychological stress brought on by the pandemic.

The Light Box segment is expected to be the largest during the forecast period

In the market for circadian rhythm sleep disorders, the Light Box segment has the largest share. One important non-pharmacological treatment for CRSDs is light therapy, which is frequently given through light boxes. This is especially true for disorders like shift work sleeps disorder and delayed sleep phase disorder. Moreover, bright artificial light produced by light boxes can help reset a person's circadian rhythms by simulating sunlight. They are extensively utilized to successfully manage CRSD symptoms in both clinical and domestic contexts. Because light therapy is widely used in CRSD treatment plans and is both non-invasive and effective, it has a significant market share in the "Light Box" category.

The Wellness Centers & Spa segment is expected to have the highest CAGR during the forecast period

The Circadian Rhythm Sleep Disorder (CRSD) market is expected to grow at the highest CAGR in the Wellness Centers & Spa segment. A growing number of wellness centers and spas are adding sleep health services to their menus, such as relaxation therapies and CRSD-focused treatments. Additionally, these environments offer a comprehensive strategy for treating sleep disorders, emphasizing relaxation and general well-being. People are going to wellness centers and spas for specialized treatments and therapies as awareness of the link between sleep and wellbeing increases.

Region with largest share:

In terms of market share for Circadian Rhythm Sleep Disorder (CRSD), North America, which includes the United States and Canada, usually has the largest share. Moreover, the region's established healthcare system, prodigious R&D endeavours, high incidence of sleep disorders, and growing consciousness regarding the importance of sleep health are the main causes of this dominance. Due to its high level of affluence and high rate of sleep disorders, the region leads the CRSD market and serves as a hub for innovations and developments in the field of sleep medicine.

Region with highest CAGR:

In the Circadian Rhythm Sleep Disorder (CRSD) market, the Asia-Pacific region is projected to have the highest CAGR. The region's strong growth is ascribed to various factors, including growing consciousness regarding sleep hygiene, the increasing occurrence of CRSDs as a result of evolving lifestyles, and the development of healthcare facilities. A greater emphasis on general health and well-being, coupled with the expansion of economies in the Asia-Pacific region, is driving demand for creative approaches to sleep disorders. Additionally, the Asia-Pacific CRSD market has experienced rapid growth due to factors such as urbanization, rising healthcare expenditures, and the region's expanding middle class. This has positioned the market as a dynamic and rapidly expanding segment with significant potential for future development.

Key players in the market

Some of the key players in Circadian Rhythm Seep Disorder market include: Carex Health, The Sunbox Company, Garmin Ltd., BMC Medical Co., Ltd, Teva Pharmaceutical Industries Ltd., Natus Medical Incorporated , Koninklijke Philips N.V., Mylan N.V., Vanda Pharmaceuticals Inc., Neuraxpharm, Sunrise System , Beurer GmbH, Lanaform N.V., Samarit Medical AG, Takeda Pharmaceutical Company, Northern Light Technologies , RedMed Inc. , ActiGraph, LLC, Verilux, Inc. and Akeda Pharmaceutical Company Limited .

Key Developments:

In August 2023, Garmin Ltd., announced it has entered into a definitive agreement to acquire JL Audio, a privately-held U.S. company that designs and manufactures audio solutions for marine, aftermarket automotive, powersports, home and RV customers.

In July 2023, Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and Alvotech, a global biotech company specializing in the development and manufacture of biosimilars, expanded their existing strategic partnership agreement. Teva will also acquire subordinated convertible bonds to be issued by Alvotech.

In December 2022, Natus Medical announced that it entered into a definitive agreement to acquire neurophysiology solution provider Micromed. Middleton, Wisconsin-based Natus expects the transaction to close in early 2023. The company elected not to disclose the financial terms of the deal. It marks the first transaction made by the company since its $1.2 billion acquisition by the ArchiMed group in July.

Treatment Types Covered:

• Therapeutic Devices
• Light Box
• Desk Lamps
• Light Visor
• Dawn Simulator
• Diagnostic Devices
• Actigraphy Sensors
• Wrist and Hand Band Actigraphy Devices
• Wearable Actigraphy Devices
• Polysomnography Devices
• Fixed Polysomnography Devices
• Portable
• Medications
• Other Treatment Types

Drug Types Covered:

• Benzodiazepines
• Non benzodiazepine Hypnotics
• Orexin Receptor Antagonists
• Melatonin Receptor Agonist
• Modafinil
• Tasimelteon
• Other Drug Types

Ages Covered:

• Children
• Adults
• Elders

Distribution Channels Covered:

• Institutional Sales
• Retail Sales

Applications Covered:

• Delayed Sleep Phase Syndrome
• Advanced Sleep Phase Syndrome
• Non-24-h sleep-wake syndrome
• Irregular Sleep-Wake Disorder
• Shift Work Disorder
• Jet Lag
• Other Applications

End Users Covered:

• Home Care Settings
• Wellness Centers & Spa
• Sleep Testing Centers
• Specialty Clinics
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Circadian Rhythm Seep Disorder Market, By Treatment Type

• 5.1 Introduction
• 5.2 Therapeutic Devices
• 5.3 Light Box
• 5.4 Desk Lamps
• 5.5 Light Visor
• 5.6 Dawn Simulator
• 5.7 Diagnostic Devices
• 5.8 Actigraphy Sensors
• 5.9 Wrist and Hand Band Actigraphy Devices
• 5.10 Wearable Actigraphy Devices
• 5.11 Polysomnography Devices
• 5.12 Fixed Polysomnography Devices
• 5.13 Portable
• 5.14 Medications
• 5.15 Other Treatment Types

6 Global Circadian Rhythm Seep Disorder Market, By Drug Type

• 6.1 Introduction
• 6.2 Benzodiazepines
• 6.3 Non benzodiazepine Hypnotics
• 6.4 Orexin Receptor Antagonists
• 6.5 Melatonin Receptor Agonist
• 6.6 Modafinil
• 6.7 Tasimelteon
• 6.8 Other Drug Types

7 Global Circadian Rhythm Seep Disorder Market, By Age

• 7.1 Introduction
• 7.2 Children
• 7.3 Adults
• 7.4 Elders

8 Global Circadian Rhythm Seep Disorder Market, By Distribution Channel

• 8.1 Introduction
• 8.2 Institutional Sales
• 8.3 Retail Sales

9 Global Circadian Rhythm Seep Disorder Market, By Application

• 9.1 Introduction
• 9.2 Delayed Sleep Phase Syndrome
• 9.3 Advanced Sleep Phase Syndrome
• 9.4 Non-24-h sleep-wake syndrome
• 9.5 Irregular Sleep-Wake Disorder
• 9.6 Shift Work Disorder
• 9.7 Jet Lag
• 9.8 Other Applications

10 Global Circadian Rhythm Seep Disorder Market, By End User

• 10.1 Introduction
• 10.2 Home Care Settings
• 10.3 Wellness Centers & Spa
• 10.4 Sleep Testing Centers
• 10.5 Specialty Clinics
• 10.6 Other End Users

11 Global Circadian Rhythm Seep Disorder Market, By Geography

• 11.1 Introduction
• 11.2 North America
  • 11.2.1 US
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 Italy
  • 11.3.4 France
  • 11.3.5 Spain
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 New Zealand
  • 11.4.6 South Korea
  • 11.4.7 Rest of Asia Pacific
• 11.5 South America
  • 11.5.1 Argentina
  • 11.5.2 Brazil
  • 11.5.3 Chile
  • 11.5.4 Rest of South America
• 11.6 Middle East & Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 UAE
  • 11.6.3 Qatar
  • 11.6.4 South Africa
  • 11.6.5 Rest of Middle East & Africa

12 Key Developments

• 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 12.2 Acquisitions & Mergers
• 12.3 New Product Launch
• 12.4 Expansions
• 12.5 Other Key Strategies

13 Company Profiling

• 13.1 Carex Health
• 13.2 The Sunbox Company
• 13.3 Garmin Ltd.
• 13.4 BMC Medical Co., Ltd
• 13.5 Teva Pharmaceutical Industries Ltd.
• 13.6 Natus Medical Incorporated
• 13.7 Koninklijke Philips N.V.
• 13.8 Mylan N.V.
• 13.9 Vanda Pharmaceuticals Inc.
• 13.10 Neuraxpharm
• 13.11 Sunrise System
• 13.12 Beurer GmbH
• 13.13 Lanaform N.V.
• 13.14 Samarit Medical AG
• 13.15 Takeda Pharmaceutical Company
• 13.16 Northern Light Technologies
• 13.17 RedMed Inc.
• 13.18 ActiGraph, LLC
• 13.19 Verilux, Inc.
• 13.20 Akeda Pharmaceutical Company Limited